VENTOLIN
LOE ApproachingNDAORALTABLET
Approved
Jul 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
VENTOLIN by GSK is 2 -adrenergic receptors compared with isoproterenol. Approved for exercise-induced bronchospasm in adult, older. First approved in 1986.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENTOLIN is an oral tablet small-molecule product approved by GSK in 1986 for an undisclosed indication. The specific mechanism of action and therapeutic class are not documented in available data, limiting clinical characterization.
LOE Approaching
Product is nearing loss of exclusivity; commercial team is likely focused on lifecycle management, cost containment, and competitive defense rather than growth initiatives.
Mechanism of Action
2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -adrenoceptors are the predominant receptors in the heart, there are also beta 2 -adrenoceptors in the human heart comprising 10% to 50%…
Indications (2)
Worked on VENTOLIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.